01—Abstract
Summary
Summary of the 10-K filed February 15, 2023. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) reported 2022 total royalty receipts of $3.23 billiona, up from $2.61 billion in 2021, with Adjusted Cash Receipts of $2.79 billion, Adjusted EBITDA of $2.57 billion and Adjusted Cash Flow of $2.24 billion.
GAAP results were weaker: total income and other revenues were $2.24 billion, operating income fell to $307.1 millionb from $1.43 billion, and net income attributable to Royalty Pharma plc declined to $42.8 million from $619.7 million. The decline was driven mainly by a $904.2 million provision for changes in expected cash flows from financial royalty assets and a $615.8 million financial royalty asset impairment, largely tied to gantenerumab, otilimab and Gavreto. The company states that its interest income and provision charges are non-cash and volatile, and that its results should not be used alone to predict future income.
The company deployed $2.5 billionc to acquire royalties in 2022, including the Trelegy royalty from Theravance for an upfront payment of $1.31 billion. Subsequent to year-end, in January 2023, it acquired royalty interests in Spinraza and pelacarsen from Ionis for up to $1.125 billion, including a $500 million upfront payment. Its portfolio includes royalties on more than 35 marketed products and 12 development-stage candidates, but the top five product franchises accounted for 69% of 2022 royalty receipts, and Vertex's cystic fibrosis franchise was the largest royalty payor.
Balance-sheet leverage is anchored by $7.3 billiond of senior unsecured notes with a weighted average coupon of 2.24%, alongside an undrawn $1.5 billion revolving credit facility. The company paid $0.76 per Class A share in 2022 in dividends, totaling $333.3 million. Its Class A shares trade on Nasdaq under RPRX, and the company is externally managed by RP Management, LLC.
02—Key points
Key Highlights
- Total royalty receipts rose to $3,231.3 million in 2022 from $2,608.5 million in 2021, including $479.5 million of accelerated Biohaven preferred share redemption payments following Pfizer's acquisition of Biohaven.
- Adjusted Cash Receipts were $2,789.3 million, Adjusted EBITDA was $2,566.3 million and Adjusted Cash Flow was $2,235.2 million, compared with $2,128.9 million, $1,944.4 million and $1,573.4 million in 2021.
- GAAP net income attributable to Royalty Pharma plc fell to $42.8 million from $619.7 million, reflecting a $904.2 million provision for changes in expected cash flows and a $615.8 million financial royalty asset impairment.
- Net cash provided by operating activities was $2,144.0 million in 2022 versus $2,017.5 million in 2021.
- The company deployed $2.5 billion in 2022 to acquire royalties, milestones and related assets, including the Trelegy royalty for an upfront payment of $1.31 billion.
- As of December 31, 2022, the company had $7.3 billion of senior unsecured notes outstanding with a 2.24% weighted average coupon, and an undrawn $1.5 billion revolving credit facility.
- Dividends of $0.76 per Class A ordinary share were paid in 2022, totaling $333.3 million; the top five product franchises accounted for 69% of 2022 royalty receipts.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2022filed February 15, 2023Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $2.24B$2.29B | −2.3% |
| R&D Expenses | $177.11M$200.08M | −11.5% |
| Operating Expenses | $1.93B$858.75M | +124.8% |
| Operating Income | $307.06M$1.43B | −78.5% |
| Interest Expense | $187.96M$166.14M | +13.1% |
| Net Income | $42.83M$619.73M | −93.1% |
| EPS (Basic) | $0.10$1.49 | −93.3% |
| EPS (Diluted) | $0.10$1.49 | −93.3% |
| Shares Outstanding (Basic) | 437.96M414.79M | +5.6% |
| Shares Outstanding (Diluted) | 437.97M414.80M | +5.6% |
05—Questions
Frequently Asked Questions
Why did GAAP net income drop so sharply in 2022 even though cash receipts grew?
The filing attributes the decline mainly to non-cash items under the effective interest method. The company recorded a $904.2 million provision for changes in expected cash flows from financial royalty assets, compared with $452.8 million in 2021, and a $615.8 million financial royalty asset impairment, with no comparable charge in 2021. The filing states that there is no direct correlation between income from financial royalty assets and royalty receipts, and that these items are volatile and unpredictable.
What drove the increase in royalty receipts in 2022?
The filing cites the $479.5 million accelerated redemption of Series A and Series B Biohaven Preferred Shares after Pfizer acquired Biohaven, growth in the cystic fibrosis franchise (up $108.9 million to $811.1 million), the new Trelegy royalty ($89.9 million), and Tremfya ($97.3 million, up $61.6 million). These were partly offset by lower receipts from Januvia, Janumet and other DPP-IVs, which substantially ended in the second quarter of 2022, and by a $40.2 million decline in Imbruvica receipts.
How concentrated is the royalty portfolio?
The filing states that no individual therapy accounted for more than 21% of 2022 royalty receipts, no therapeutic area more than 29%, and no marketer more than 25%. However, the top five product franchises accounted for 69% of royalty receipts, and Vertex was the largest royalty payor, representing 36% of total income and other revenues in 2022.
What are the main risks to future royalty cash flows?
The filing identifies sales risks of royalty-bearing products, reliance on a limited number of products, the timing and assumptions behind royalty durations, and the expiration of key patents, including Trikafta's expected 2037 patent expiration that may lead to sales declines from generic entry. It also notes that marketers control commercialization and that development-stage candidates may fail to reach the market.
What is the company's financing and capital structure position?
At December 31, 2022, the company had $7.3 billion of senior unsecured notes, with $997.5 million classified as current portion of long-term debt, and $1.7 billion in cash and cash equivalents. The notes carry a 2.24% weighted average coupon and a weighted average maturity of approximately 12 years, and the $1.5 billion revolving credit facility was undrawn. The company was in compliance with its debt covenants as of year-end.
06—Continue